MaxCyte (MXCT) Stock Price, News & Analysis

Company Overview

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Key Stats

• Today's Range: $3.07 to $3.14
• 50-Day Range: $3.06 to $5.10
• 52-Week Range: $2.76 to $5.26
• Volume: 235,484 shs
• Average Volume: 508,827 shs
• Market Capitalization: $328.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.67
• Consensus Rating: Buy

MaxCyte Stock Analysis - MarketRank™

MaxCyte scored higher than 54% of companies evaluated by MarketBeat, and ranked 469th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

MaxCyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

MaxCyte has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MaxCyte are expected to grow in the coming year, from ($0.42) to ($0.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MaxCyte is -9.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MaxCyte is -9.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MaxCyte has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.77% of the float of MaxCyte has been sold short.

Short Interest Ratio / Days to Cover

MaxCyte has a short interest ratio ("days to cover") of 4.8.

Change versus previous month

Short interest in MaxCyte has recently decreased by 2.53%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MaxCyte does not currently pay a dividend.

Dividend Growth

MaxCyte does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.77% of the float of MaxCyte has been sold short.

Short Interest Ratio / Days to Cover

MaxCyte has a short interest ratio ("days to cover") of 4.8.

Change versus previous month

Short interest in MaxCyte has recently decreased by 2.53%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.35

News Sentiment

MaxCyte has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for MaxCyte this week, compared to 2 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, MaxCyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,265.00 in company stock.

Percentage Held by Insiders

Only 3.00% of the stock of MaxCyte is held by insiders.

Percentage Held by Institutions

68.81% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MXCT Stock Analysis - Frequently Asked Questions

How have MXCT shares performed this year?

MaxCyte's stock was trading at $4.16 at the start of the year. Since then, MXCT shares have decreased by 25.6% and is now trading at $3.0950.
View the best growth stocks for 2025 here.

How were MaxCyte's earnings last quarter?

MaxCyte, Inc. (NASDAQ:MXCT) posted its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. The company had revenue of $8.16 million for the quarter, compared to analysts' expectations of $7.50 million. MaxCyte had a negative net margin of 78.36% and a negative trailing twelve-month return on equity of 16.00%.

When did MaxCyte IPO?

MaxCyte (MXCT) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 12,000,000 shares at a price of $11.50-$13.50 per share.

Who are MaxCyte's major shareholders?

Top institutional investors of MaxCyte include Cadian Capital Management LP (8.83%), Vanguard Group Inc. (5.13%), Mirabella Financial Services LLP (3.50%) and River Global Investors LLP (3.08%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, John Joseph Johnston, Douglas J Swirsky, Maher Masoud, Richard Douglas, David I Sandoval, Ali Soleymannezhad and Thomas M Ross.
View institutional ownership trends.

How do I buy shares of MaxCyte?

Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MaxCyte own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 3/24/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Commercial physical research
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:MXCT
• CIK: 1287098
• Web: maxcyte.com
• Phone: 301-944-1700
• Fax: 301-944-1703
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.67
• High Stock Price Target: $11.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +180.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-37,920,000.00
• Net Margins: -78.36%
• Pretax Margin: -78.37%
• Return on Equity: -16.00%
• Return on Assets: -13.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.81
• Quick Ratio: 9.22

Sales & Book Value

• Annual Sales: $38.63 million
• Price / Sales: 8.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.23 per share
• Price / Book: 1.39

Miscellaneous

• Outstanding Shares: 106,028,000
• Free Float: 102,671,000
• Market Cap: $327.63 million
• Optionable: Optionable
• Beta: 1.35